Articles 124 www.thelancet.com   Vol 381   January 12, 20136 Klonoﬀ   DC, Buse JB, Nielsen LL, et al. Exenatide eﬀ  ects on diabetes,  obesity, cardiovascular risk factors and hepatic biomarkers in patients  with type 2 diabetes treated for at least 3 years. Curr Med Res Opin   2008; 24: 275–86. 7 Bergenstal RM, Wysham C, MacConell L, et al. Eﬃ   cacy and safety  of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431–39. 8 Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide  compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234–43. 9 Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus  twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240–50.